How to benchmark life sciences project data

life science

It’s sometimes said life sciences projects are so bespoke comparisons between them are meaningless, that’s far from the case

As the life sciences sector powers ahead, fuelled by funding for further research into Covid and other health priorities, construction and refurbishment projects will be a core area of activity for the sector as it scales-up and diversifies its work. Competition among pharmaceutical giants has always been fierce and businesses in the sector will now gain an advantage if they can assess their performance in terms of real estate against peers. But how to do it in such a competitive industry and one where each construction and refurbishment project is highly bespoke?

There is a common perception that so diverse are life science real estate facilities that meaningful benchmarking is impossible. In fact, benchmarking life sciences real estate projects can be done, and Linesight is proving it with a pioneering new initiative involving sixteen of the world’s leading life sciences companies, including Pfizer and AstraZeneca.

Already registered? Login here

To continue enjoying, sign up for free guest access

Existing subscriber? LOGIN


Stay at the forefront of thought leadership with news and analysis from award-winning journalists. Enjoy company features, CEO interviews, architectural reviews, technical project know-how and the latest innovations.

  • Limited access to
  • Breaking industry news as it happens
  • Breaking, daily and weekly e-newsletters

Get your free guest access  SIGN UP TODAY

Gated access promo

Subscribe now for unlimited access


Subscribe to Building today and you will benefit from:

  • Unlimited access to all stories including expert analysis and comment from industry leaders
  • Our league tables, cost models and economics data
  • Our online archive of over 10,000 articles
  • Building magazine digital editions
  • Building magazine print editions
  • Printed/digital supplements

Subscribe now for unlimited access.

View our subscription options and join our community